Luigino Calzetta1, Mario Cazzola2, Maria Gabriella Matera3, Paola Rogliani1. 1. Department of Experimental Medicine, Unit of Respiratory Medicine, University of Rome "Tor Vergata," Rome, Italy. 2. Department of Experimental Medicine, Unit of Respiratory Medicine, University of Rome "Tor Vergata," Rome, Italy. Electronic address: mario.cazzola@uniroma2.it. 3. Department of Experimental Medicine (Dr Matera), Unit of Pharmacology, University of Campania "Luigi Vanvitelli," Naples, Italy.
Abstract
BACKGROUND: Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination is commonly prescribed to treat COPD; therefore, we performed a meta-analysis on the effect of adding a long-acting muscarinic receptor antagonist (LAMA) to ICS/LABA combination in COPD. METHODS: Studies were identified by searching in different databases the randomized controlled trials that investigated the effect of ICS/LABA/LAMA combination in COPD. The primary end points were the effect of triple therapy on trough FEV1, risk of acute exacerbation of COPD (AECOPD), and risk of cardiovascular serious adverse events (SAEs), compared with ICS/LABA combination. The Grading of Recommendations Assessment, Development, and Evaluation system was used to assess the quality of evidence. RESULTS: Thirteen randomized controlled trials including 15,519 patients with COPD (ICS/LABA/LAMA combination, 53.1%; ICS/LABA combination, 46.9%) were meta-analyzed. ICS/LABA/LAMA combination improved trough FEV1 (mean difference, +104.86 mL; 95% CI, 86.74-122.99; high quality of evidence) and protected against AECOPD (relative risk, 0.78; 95% CI, 0.71-0.85; high quality of evidence) vs ICS/LABA combination. For every approximately four patients treated with triple therapy, one increased FEV1 > 100 mL, and approximately 26 patients had to be treated for 1 year with ICS/LABA/LAMA combination to prevent one AECOPD, compared with ICS/LABA combination. Adding a LAMA to ICS/LABA therapy did not modulate the risk of cardiovascular SAEs (moderate quality of evidence). CONCLUSIONS: Triple therapy provides significant clinical benefit in patients with COPD on ICS/LABA combination. ICS/LABA therapy can be escalated to triple therapy without a real risk to increase cardiovascular SAEs when a LAMA is added to the combination. TRIAL REGISTRY: ClinicalTrials.gov; No.: CRD42018095300; URL: www.clinicaltrials.gov.
BACKGROUND: Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination is commonly prescribed to treat COPD; therefore, we performed a meta-analysis on the effect of adding a long-acting muscarinic receptor antagonist (LAMA) to ICS/LABA combination in COPD. METHODS: Studies were identified by searching in different databases the randomized controlled trials that investigated the effect of ICS/LABA/LAMA combination in COPD. The primary end points were the effect of triple therapy on trough FEV1, risk of acute exacerbation of COPD (AECOPD), and risk of cardiovascular serious adverse events (SAEs), compared with ICS/LABA combination. The Grading of Recommendations Assessment, Development, and Evaluation system was used to assess the quality of evidence. RESULTS: Thirteen randomized controlled trials including 15,519 patients with COPD (ICS/LABA/LAMA combination, 53.1%; ICS/LABA combination, 46.9%) were meta-analyzed. ICS/LABA/LAMA combination improved trough FEV1 (mean difference, +104.86 mL; 95% CI, 86.74-122.99; high quality of evidence) and protected against AECOPD (relative risk, 0.78; 95% CI, 0.71-0.85; high quality of evidence) vs ICS/LABA combination. For every approximately four patients treated with triple therapy, one increased FEV1 > 100 mL, and approximately 26 patients had to be treated for 1 year with ICS/LABA/LAMA combination to prevent one AECOPD, compared with ICS/LABA combination. Adding a LAMA to ICS/LABA therapy did not modulate the risk of cardiovascular SAEs (moderate quality of evidence). CONCLUSIONS: Triple therapy provides significant clinical benefit in patients with COPD on ICS/LABA combination. ICS/LABA therapy can be escalated to triple therapy without a real risk to increase cardiovascular SAEs when a LAMA is added to the combination. TRIAL REGISTRY: ClinicalTrials.gov; No.: CRD42018095300; URL: www.clinicaltrials.gov.
Authors: Arnaud Bourdin; Nicolas Molinari; Gary T Ferguson; Barinder Singh; Mohd Kashif Siddiqui; Ulf Holmgren; Mario Ouwens; Martin Jenkins; Enrico De Nigris Journal: Adv Ther Date: 2021-04-30 Impact factor: 3.845
Authors: Nicola C Day; Subramanya Kumar; Gerard Criner; Mark Dransfield; David M G Halpin; MeiLan K Han; C Elaine Jones; Morrys C Kaisermann; Sally Kilbride; Peter Lange; David A Lomas; Neil Martin; Fernando J Martinez; Dave Singh; Robert Wise; David A Lipson Journal: Respir Res Date: 2020-06-05
Authors: Jose Luis Lopez-Campos; Laura Carrasco-Hernandez; Esther Quintana-Gallego; Carmen Calero-Acuña; Eduardo Márquez-Martín; Francisco Ortega-Ruiz; Joan B Soriano Journal: Ther Adv Respir Dis Date: 2019 Jan-Dec Impact factor: 4.031